Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

RCT (n=572) found that atezolizumab resulted in longer overall survival than platinum-based chemotherapy in subgroup of patients with EGFR and ALK wild-type tumours with highest expression of PD-L1 (20.2 vs. 13.1 months; HR death, 0.59; p=0.01).

Source:

New England Journal of Medicine